The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -45,650 | -46,105 | -257,820 | -70,128 |
| Depreciation and amortization | 2,869 | 1,587 | 1,023 | 2,013 |
| Operating lease liability | - | - | 180 | 343 |
| Amortization of debt issuance costs and debt discount | 1,028 | 409 | 0 | 0 |
| Non-cash operating lease cost | 643 | 270 | 185 | 357 |
| Loss on debt extinguishment, net | - | -6,247 | -1,103 | - |
| Non-cash interest expense for deferred consideration | 324 | - | - | - |
| Stock-based compensation | 3,629 | 5,643 | 3,256 | 6,593 |
| Fair value of gloperba-elyxyb rpa liability expensed | - | 500 | - | - |
| Fair value of treasury stock expensed - tranche b and oramed note | - | 3,557 | - | - |
| Fair value of september 2025 warrants expensed - tranche b modification | - | 3,091 | - | - |
| Gain on warrant derivative liabilities | 25,709 | 37,630 | -58,357 | -1,966 |
| Goodwill impairment | - | 73,358 | - | - |
| Loss on compound derivative of scilex-st. james loans | -21,829 | - | - | - |
| Financing costs and allocated expense for financial instruments at fair value | 0 | -7,148 | 3,091 | 4,057 |
| In-process research and development expense | 0 | 0 | 510 | 4,916 |
| Realized (gain) loss on equity method investment, net | - | 4,657 | - | - |
| Transaction costs expensed related to semnur business combination | - | 0 | 140,000 | - |
| Realized loss on securities | -3,071 | -199 | - | - |
| Change in fair value of debt and liability instruments | 2,797 | -11,160 | 22,031 | 14,480 |
| Change in fair value of equity investments | - | 5,590 | -8,282 | - |
| Change in fair value of digital assets | - | 16,882 | -4,702 | - |
| Unrealized loss on digital assets | -18,064 | -30,200 | - | - |
| Change in fair value of equity method investment, net | - | 54,759 | - | - |
| Unrealized loss on emi | -31,710 | - | - | - |
| Realized (gain) loss on emi | 42,338 | 19,218 | - | - |
| Allowances for expected credit losses | 800 | - | 0 | - |
| Non- cash revenue | 1,131 | - | - | - |
| Allowances for expected credit losses | - | 0 | - | - |
| Gain from property in kind dividend | 525 | - | - | - |
| Other | 1,614 | -188 | 98 | 77 |
| Accounts receivables, net | -4,597 | 664 | -4,826 | -9,675 |
| Inventory | -257 | -509 | -1,378 | 88 |
| Prepaid expenses and other | -614 | 3,523 | -5,357 | -1,466 |
| Other long-term assets | 605 | 3 | 0 | 0 |
| Accounts payable | 15,812 | 1,768 | 4,497 | 6,856 |
| Accrued payroll | 631 | 15 | -1,238 | 128 |
| Accrued expenses | -7,805 | -293 | 14,295 | 599 |
| Accrued rebates and fees | 15,758 | 18,375 | 20,441 | 30,423 |
| Operating lease liability | - | -857 | - | - |
| Other liabilities | 3,394 | - | - | - |
| Other long-term liabilities | 3 | 11 | 4 | 10 |
| Purchase of equity securities | - | 0 | 0 | - |
| Net cash proceeds from operating activities | -1,107 | -17,471 | 8,230 | 13,057 |
| Cash paid for in-process research and development, net | 0 | 0 | 0 | 200 |
| Purchase of patent | -2,900 | - | - | - |
| Acquisition consideration paid in cash for romeg intangible asset acquisition | 150 | 150 | 150 | 300 |
| Cash paid to settle datavault obligation | - | 9,230 | - | - |
| Payment made for pa ops investment | 200 | 1,000 | - | - |
| Purchases of bitcoin | 18,698 | 15,837 | - | - |
| Purchase of property, plant, and equipment | - | 133 | - | - |
| Exercise of prefunded warrant | - | -27 | - | - |
| Repayments on promissory note | -750 | -962 | - | - |
| Purchase of preferred shares of vivasor | 299 | 9,000 | - | - |
| Issuance of convertible note receivable for qscan | 20,000 | - | - | - |
| Sale of datavault shares for cash, net | 31,392 | 39,606 | - | - |
| Cash consideration paid in connection with warrant repurchase | - | 0 | - | - |
| Payment made for datavault licenses | -500 | - | - | - |
| Cash assumed in semnur business combination | - | 2 | 33 | - |
| Vivasor cash acquired | - | 1,517 | - | - |
| Sale of marketable securities | 2,945 | - | - | - |
| Repayment of convertible debentures | - | 0 | 0 | 0 |
| Purchase of convertible promissory note from denali | 0 | 0 | 2 | 48 |
| Repayment of tranche b notes | - | 4,565 | 7,093 | 8,874 |
| Net cash used for investing activities | -9,160 | 4,784 | -152 | -548 |
| Proceeds from issuance of shares under standby equity purchase agreements and atm sales agreement | - | 0 | 0 | 0 |
| Proceeds from issuance of revolving facility | - | 0 | 0 | 0 |
| Proceeds from issuance of fsf deposit | - | 0 | 0 | 0 |
| Payments of deferred transaction costs related to semnur merger | - | -263 | - | 263 |
| Proceeds from exercise of april 2024 rdo warrants and december 2024 rdo warrants | - | 10,121 | 10,237 | - |
| Proceeds from exercise of december 2024 rdo warrants for common stock | - | 10,237 | - | - |
| Proceeds from stock options and warrants exercised and espp | - | 6 | 0 | 17 |
| Proceeds from issuance of shares under direct offerings | - | 0 | 0 | 0 |
| Payments of direct offering issuance costs | - | 0 | 0 | 0 |
| Proceeds from issuance of tranche b notes and purchased revenue liability | - | 0 | - | - |
| Payments of debt issuance costs | - | 0 | 71 | - |
| Repayment of revolving facility | - | 0 | 0 | 0 |
| Cash consideration paid in connection with the repurchase of penny warrants | - | 14,000 | 13,000 | - |
| Repayment of tranche b note | 6,319 | 0 | 0 | 0 |
| Deferred Revenue Refund Payments1 | 794 | 806 | 1,217 | 1,156 |
| Payments for vivasor debt | 745 | 558 | - | - |
| Acquisition of controlling interest in vivasor | 1,500 | - | - | - |
| Repayment of tranche b notes principal and interest | 0 | - | - | - |
| Payments On Purchased Revenue Liability | 0 | - | - | - |
| Transaction costs paid in connection with issuance of common stock and exchange of april 2024 rdo warrants and december 2024 rdo warrants for november 2025 warrants | - | 1,745 | - | - |
| Payments in lieu of fractional shares for reverse stock split | - | 0 | 0 | -1 |
| Transaction costs paid in connection with share repurchase | 0 | 0 | 300 | 696 |
| Payments for the termination of tumim purchase agreement | - | -2,700 | - | - |
| Excise tax paid in connection with share repurchase | 0 | 0 | 151 | 709 |
| Proceeds from issuance of st james loan, net of issuance costs | -15,502 | -21,528 | - | - |
| Transaction costs paid related to semnur business combination | 0 | - | 0 | - |
| Net cash provided by (used for) financing activities | 9,144 | 17,520 | -11,299 | -11,682 |
| Effect of exchange rate changes on cash | -481 | -756 | - | - |
| Net change in cash and cash equivalents | -1,604 | 4,077 | -3,221 | 827 |
| Cash and cash equivalents at beginning of period | 4,955 | 878 | 3,272 | - |
| Cash and cash equivalents at end of period | 3,351 | 4,955 | 878 | - |
Scilex Holding Co (SCLXW)
Scilex Holding Co (SCLXW)